Swedish Orphan Biovitrum AB has welcomed its new Chief Financial Officer who will join Sobi in late spring. Henrik Stenqvist will also be a member of Sobi’s Executive Committee, Sobi said on Monday in its press release.
Henrik Stenqvist has comprehensive experience from the pharmaceutical industry with 25 years in finance and management positions. He joins Sobi from a position as CFO of Recipharm. Prior to that, Henrik Stenqvist served as the CFO of the Meda Group, where he played an instrumental role in the transformation of Meda from a small Nordic player to a leading international specialty pharma, executing numerous acquisitions as well as the integration of these.
Guido Oelkers, CEO and President of Sobi, and Henrik Stenqvist both expect Stenqvist’s experience can contribute to realising Sobi’s growth strategy.
Oelkers said: “It is a pleasure to welcome Henrik to Sobi. His experience from the pharmaceutical industry and specifically from acquisitions and deal making in specialty pharma will be of immense value for Sobi on our journey to become a global leader in rare diseases and specialty care.”